Increased frequency of circulating invariant natural killer T cells in malignant pleural mesothelioma patients

Cancer Biology and Therapy

Volumn 13, Issue 9, 2012, Pages 702-711

  Altomare, Emanuela ^a   Fallarini, Silvia ^a   Biaggi, Gabriele ^b   Gattoni, Elisabetta ^b   Botta, Mario ^b   Lombardi, Grazia ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Casale Monferrato Hospital   (Italy)

Author keywords

Asbestos; Cancer; Cytokines; FACS; iNKT cells; MPM; T lymphocytes

Indexed keywords

ASBESTOS; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE FREQUENCY; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; MALE; NATURAL KILLER T CELL; PHENOTYPE; PLEURA MESOTHELIOMA; PROTEIN EXPRESSION; SARCOMATOID CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LYMPHOCYTE COUNT; MALE; MESOTHELIOMA; MIDDLE AGED; NATURAL KILLER T-CELLS; NEOPLASM STAGING; PHENOTYPE; PLEURAL NEOPLASMS;

EID: 84863435279     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.20553     Document Type: Article

References (62)

1. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, et al. Malignant mesothelioma: facts, myths and hypotheses. J Cell Physiol 2012; 227:44-58; PMID:21412769; http://dx.doi.org/10.1002/jcp.22724.
2. Bueno R, Reblando J, Glickman J, Jaklitsch MT, Lukanich JM, Sugarbaker DJ. Pleural biopsy: a reliable method for determining the diagnosis but not subtype in mesothelioma. Ann Thorac Surg 2004; 78:1774-6; PMID:15511473; http://dx.doi.org/10.1016/j.athoracsur.2004.05.007.
3. Pistolesi M, Rusthoven J. Malignant pleural mesothelioma: update, current management and newer therapeutic strategies. Chest 2004; 126:1318-29; PMID:15486399; http://dx.doi.org/10.1378/chest.126.4.1318.
4. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis and pathogenesis. Curr Treat Options Oncol 2008; 9:147-57; PMID:18709470; http://dx.doi.org/10.1007/s11864-008-0067-z.
5. Ak G, Metintas S, Metintas M, Yildirim H, Erginel S, Kurt E, et al. Prognostic factors according to the treatment schedule in malignant pleural mesothelioma. J Thorac Oncol 2009; 4:1425-30; PMID:19752758; http://dx.doi.org/10.1097/JTO.0b013e3181ba2033.
6. Miura Y, Nishimura Y, Maeda M, Murakami S, Hayashi H, Fukuoka K, et al. Immunological alterations found in mesothelioma patients and supporting experimental evidence. Environ Health Prev Med 2008; 13:55-9; PMID:19568881; http://dx.doi.org/10.1007/s12199-007-0012-y.
7. Murakami S, Nishimura Y, Maeda M, Kumagai N, Hayashi H, Chen Y, et al. Cytokine alteration and speculated immunological pathophysiology in silicosis and asbestos-related diseases. Environ Health Prev Med 2009; 14:216-22; PMID:19568841; http://dx.doi.org/10.1007/s12199-008-0063-8.
8. Leigh RA, Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982; 61:1007-9; PMID:7089768.
9. Lew F, Tsang P, Holland JF, Warner N, Selikoff IJ, Bekesi JG. High frequency of immune dysfunctions in asbestos workers and in patients with malignant mesothelioma. J Clin Immunol 1986; 6:225-33; PMID:2424930; http://dx.doi.org/10.1007/BF00918702.
10. Tsang PH, Chu FN, Fischbein A, Bekesi JG. Impairments in functional subsets of T-suppressor (CD8) lymphocytes, monocytes and natural killer cells among asbestos-exposed workers. Clin Immunol Immunopathol 1988; 47:323-32; PMID:2967138; http://dx.doi.org/10.1016/S0090-1229(88)80009-6.
11. Mutti L, Valle MT, Balbi B, Orengo AM, Lazzaro A, Alciato P, et al. Primary human mesothelioma cells express class II MHC, ICAM-1 and B7-2 and can present recall antigens to autologous blood lymphocytes. Int J Cancer 1998; 78:740-9; PMID:9833768; http://dx.doi.org/10.1002/(SICI)1097-0215(19981209)78: 6〈740::AID-IJC12〉3.0.CO;2-5.
12. Robinson C, Robinson BW, Lake RA. Sera from patients with malignant mesothelioma can contain autoantibodies. Lung Cancer 1998; 20:175-84; PMID:9733052; http://dx.doi.org/10.1016/S0169-5002(98)00014-2.
13. Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, et al. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients. Clin Cancer Res 2005; 11:3814-20; PMID:15897581; http://dx.doi.org/10.1158/1078-0432.CCR-04- 2304.
14. Castagneto B, Zai S, Mutti L, Lazzaro A, Ridolfi R, Piccolini E, et al. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients. Lung Cancer 2001; 31:303-10; PMID:11165411; http://dx.doi.org/10.1016/S0169-5002(00)00192-6.
15. Powell A, Creaney J, Broomfield S, Van Bruggen I, Robinson B. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer 2006; 52:189-97; PMID:16563560; http://dx.doi.org/10.1016/j. lungcan.2006.01.007.
16. Hassan R, Ho M. Mesothelin targeted cancer immunotherapy. Eur J Cancer 2008; 44:46-53; PMID:17945478; http://dx.doi.org/10.1016/j.ejca.2007.08.028.
17. Alì G, Boldrini L, Lucchi M, Picchi A, Dell'Omodarme M, Prati MC, et al. Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact. Br J Cancer 2009; 101:1869-75; PMID:19935800; http://dx.doi.org/10.1038/sj.bjc.6605438.
18. Monnet I, Breau JL, Moro D, Lena H, Eymard JC, Ménard O, et al. Intrapleural infusion of activated macrophages and gammainterferon in malignant pleural mesothelioma: a phase II study. Chest 2002; 121:1921-7; PMID:12065358; http://dx.doi.org/10.1378/chest.121.6.1921.
19. Grégoire M. What's the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr 2010; 4:153-61; PMID:20179421; http://dx.doi.org/10.4161/cam.4.1.11361.
20. Kawano T, Cui J, Koezuka Y, Toura I, Kaneko Y, Sato H, et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci USA 1998; 95:5690-3; PMID:9576945; http://dx.doi.org/10.1073/pnas.95.10.5690.
21. Molling JW, Moreno M, de Groot J, van der Vliet HJ, von Blomberg BM, van den Eertwegh AJ, et al. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. Immunol Lett 2008; 118:36-43; PMID:18405982; http://dx.doi.org/10. 1016/j.imlet.2008.02.007.
22. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005; 23:877-900; PMID:15771592; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115742.
23. Norris S, Doherty DG, Collins C, McEntee G, Traynor O, Hegarty JE, et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Valpha24-JalphaQ and gammadelta T cell receptor bearing cells. Hum Immunol 1999; 60:20-31; PMID:9952024; http://dx.doi.org/10.1016/S0198-8859(98) 00098-6.
24. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004; 4:231-7; PMID:15039760; http://dx.doi.org/10.1038/nri1309.
25. Taniguchi M, Tashiro T, Dashtsoodol N, Hongo N, Watarai H. The specialized iNKT cell system recognizes glycolipid antigens and bridges the innate and acquired immune systems with potential applications for cancer therapy. Int Immunol 2010; 22:1-6; PMID:19858073; http://dx.doi.org/10.1093/ intimm/dxp104.
26. van der Vliet HJ, Molling JW, von Blomberg BM, Nishi N, Kölgen W, van den Eertwegh AJ, et al. The immunoregulatory role of CD1d-restricted natural killer T cells in disease. Clin Immunol 2004; 112:8-23; PMID:15207777; http://dx.doi.org/10.1016/j.clim.2004.03.003.
27. Das R, Sant'Angelo DB, Nichols KE. Transcriptional control of invariant NKT cell development. Immunol Rev 2010; 238:195-215; PMID:20969594; http://dx.doi.org/10.1111/j.1600-065X.2010.00962.x.
28. Chan AC, Serwecinska L, Cochrane A, Harrison LC, Godfrey DI, Berzins SP. Immune characterization of an individual with an exceptionally high natural killer T cell frequency and her immediate family. Clin Exp Immunol 2009; 156:238-45; PMID:19250277; http://dx.doi.org/10.1111/j.1365-2249.2009.03888.x.
29. Montoya CJ, Pollard D, Martinson J, Kumari K, Wasserfall C, Mulder CB, et al. Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cellclonotypic monoclonal antibody, 6B11. Immunology 2007; 122:1-14; PMID:17662044; http://dx.doi.org/10. 1111/j.1365-2567.2007.02647.x.
30. Lin H, Nieda M, Rozenkov V, Nicol AJ. Analysis of the effect of different NKT cell subpopulations on the activation of CD4 and CD8 T cells, NK cells and B cells. Exp Hematol 2006; 34:289-95; PMID:16543063; http://dx.doi.org/10.1016/ j.exphem.2005.12.008.
31. Kim CH, Butcher EC, Johnston B. Distinct subsets of human Valpha24-invariant NKT cells: cytokine responses and chemokine receptor expression. Trends Immunol 2002; 23:516-9; PMID:12401396; http://dx.doi.org/10. 1016/S1471-4906(02)02323-2.
32. Baev DV, Peng XH, Song L, Barnhart JR, Crooks GM, Weinberg KI, et al. Distinct homeostatic requirements of CD4+ and CD4- subsets of Valpha24-invariant natural killer T cells in humans. Blood 2004; 104:4150-6; PMID:15328159; http://dx.doi.org/10.1182/blood-2004-04-1629.
33. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008; 101:277-348; PMID:19055947; http://dx.doi.org/10.1016/S0065- 230X(08)00408-9.
34. Bourgeois E, Van LP, Samson M, Diem S, Barra A, Roga S, et al. The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFNgamma production. Eur J Immunol 2009; 39:1046-55; PMID:19266498; http://dx.doi.org/10.1002/eji.200838575.
35. +NK cells in vitro. J Immunol 2000; 165:1659-64; PMID:10903777.
36. Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 2011; 140:160-6; PMID:21233022; http://dx.doi.org/10.1016/j.clim.2010.12.010.
37. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, Wilson SB, et al. Loss of IFNgamma production by invariant NK T cells in advanced cancer. J Immunol 2001; 167:4046-50; PMID:11564825.
38. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, Nicol AJ. Modulation of human Valpha24(+) Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 2004; 91:1880-6; PMID:15520823; http://dx.doi.org/10.1038/sj.bjc.6602218.
39. Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002;8:3702-9; PMID:12473579.
40. Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, et al. A phase I-II study of alphagalactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009; 182:2492-501; PMID:19201905; http://dx.doi.org/10.4049/jimmunol.0800126.
41. Fujii S, Takayama T, Asakura M, Aki K, Fujimoto K, Shimizu K. Dendritic cell-based cancer immunotherapies. Arch Immunol Ther Exp (Warsz) 2009; 57:189-98; PMID:19479202; http://dx.doi.org/10.1007/s00005-009-0025-x.
42. McCaughey WT, Colby TV, Battifora H, Churg A, Corson JM, Greenberg SD, et al. Diagnosis of diffuse malignant mesothelioma: experience of a US/Canadian Mesothelioma Panel. Mod Pathol 1991; 4:342-53; PMID:2068061.
43. Fallarini S, Paoletti T, Panza L, Lombardi G. Alphagalactosylceramide modulates the induction of indoleamine-2,3-dioxygenase in antigen presenting cells. Biochem Pharmacol 2008; 76:738-50; PMID:18671950; http://dx.doi.org/10. 1016/j.bcp.2008.07.001.
44. Fujiwara T, Oda K, Yokota S, Takatsuki A, Ikehara Y. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem 1988; 263:18545-52; PMID:3192548.
45. Chirieac LR, Corson JM. Pathologic evaluation of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 2009; 21:121-4; PMID:19822283; http://dx.doi.org/10.1053/j.semtcvs.2009.06.005.
46. + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 2005; 116:87-93; PMID:15756674; http://dx.doi.org/10.1002/ijc.20998.
47. Metelitsa LS. Flow cytometry for natural killer T cells: multi-parameter methods for multifunctional cells. Clin Immunol 2004; 110:267-76; PMID:15047204; http://dx.doi.org/10.1016/j.clim.2003.11.005.
48. Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med 2010; 134:1645-58; PMID:21043818.
49. Rom WN, Palmer PE. The spectrum of asbestos-related diseases. West J Med 1974; 121:10-21; PMID:4601063.
50. Donaldson K, Aitken R, Tran L, Stone V, Duffin R, Forrest G, et al. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006; 92:5-22; PMID:16484287; http://dx.doi.org/10.1093/toxsci/kfj130.
51. Donaldson K, Murphy FA, Duffin R, Poland CA. Asbestos, carbon nanotubes and the pleural mesothelium: a review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010; 7:5; PMID:20307263; http://dx.doi.org/10.1186/1743-8977-7- 5.
52. Gansert JL, Kiessler V, Engele M, Wittke F, Röllinghoff M, Krensky AM, et al. Human NKT cells express granulysin and exhibit antimycobacterial activity. J Immunol 2003; 170:3154-61; PMID:12626573.
53. Ho LP, Urban BC, Thickett DR, Davies RJ, McMichael AJ. Deficiency of a subset of T-cells with immunoregulatory properties in sarcoidosis. Lancet 2005; 365:1062-72; PMID:15781102.
54. Kusner DJ. Mechanisms of mycobacterial persistence in tuberculosis. Clin Immunol 2005; 114:239-47; PMID:15721834; http://dx.doi.org/10.1016/j.clim.2004. 07.016.
55. Becquemin MH, Bertholon JF, Attoui M, Roy F, Roy M, Dautzenberg B. Particle size in the smoke produced by six different types of cigarette. Rev Mal Respir 2007; 24:845-52; PMID:17925666; http://dx.doi.org/10.1016/S0761-8425(07) 91386-8.
56. Domagala-Kulawik J. Effects of cigarette smoke on the lung and systemic immunity. J Physiol Pharmacol 2008; 59:19-34; PMID:19218630.
57. Sköld CM, Blaschke E, Eklund A. Transient increases in albumin and hyaluronan in bronchoalveolar lavage fluid after quitting smoking: possible signs of reparative mechanisms. Respir Med 1996; 90:523-9; PMID:8984526; http://dx.doi.org/10.1016/S0954-6111(96)90144-4.
58. Hogan AE, Corrigan MA, O'Reilly V, Gaoatswe G, O'Connell J, Doherty DG, et al. Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses. Clin Immunol 2011; 140:229-35; PMID:21684213; http://dx.doi.org/10.1016/j.clim.2011.01.011.
59. Ilavská S, Jahnová E, Tulinská J, Horváthová M, Dusinská M, Wsolová L, et al. Immunological monitoring in workers occupationally exposed to asbestos. Toxicology 2005; 206:299-308; PMID:15588921; http://dx.doi.org/10.1016/j.tox. 2004.09.004.
60. Parekh VV, Wilson MT, Olivares-Villagómez D, Singh AK, Wu L, Wang CR, et al. Glycolipid antigen induces long-term natural killer T cell anergy in mice. J Clin Invest 2005; 115:2572-83; PMID:16138194; http://dx.doi.org/10.1172/ JCI24762.
61. Otsuki T, Maeda M, Murakami S, Hayashi H, Miura Y, Kusaka M, et al. Immunological effects of silica and asbestos. Cell Mol Immunol 2007; 4:261-8; PMID:17764616.
62. Maeda M, Miura Y, Nishimura Y, Murakami S, Hayashi H, Kumagai N, et al. Immunological changes in mesothelioma patients and their experimental detection. Clin Med Circ Respirat Pulm Med 2008; 2:11-7; PMID:21157517.